The Immunoadoptive Cell Therapy Private Limited (ImmunoACT), based in Mumbai, India, on October 13, 2023, announced the Central Drugs Standard Control Organization (CDSCO)’s approval for the use of the country’s first chimeric antigen receptor (CAR-T) cell therapy for the treating relapsed-refractory B-cell lymphoma and leukemia.
Trending
- How Sokoto, UNICEF are rewriting the story of child development – Usman M. Binji
- Tinubu signs executive order to coordinate crypto regulation, establishes CBN-led council
- UNICEF urges stronger leadership, community action to tackle child health challenges
- Fact-check: Viral images of “300 bandits” in Zamfara are from South Africa, by Shehu Muhammad Shehu
- CBN’s proposed banking rules may push Zenith, UBA, Fidelity into holding company structure
- Ogun distributes agricultural Inputs to 2,740 cassava farmers
- Nigeria key to achieving PPR-free West Africa, Continent — AU-IBAR
- NALDA establishes Renewed hope mega farm estates in 4 states
